Email updates

Keep up to date with the latest news and content from BMC Genomics and BioMed Central.

Open Access Highly Accessed Research article

Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo

Mounia Lagha6, Takahiko Sato6, Béatrice Regnault1, Ana Cumano2, Aimée Zuniga3, Jonathan Licht4, Frédéric Relaix5 and Margaret Buckingham6*

Author Affiliations

1 Genopole, Institut Pasteur, 28 Rue du Dr Roux, 75015 Paris, France

2 INSERM U668, Département d'Immunologie, Institut Pasteur, 25 Rue du Dr Roux, 75015 Paris, France

3 DBM/Center for Biomedicine, Basel, Switzerland

4 Northwestern University, Chicago, USA

5 UMRS787, INSERM-UPMC-Paris VI, Institut de Myologie, Faculté de Médecine Pitié-Salpétrière, 75634 Paris, France

6 CNRS URA 2578, Département de Biologie du Développement, Institut Pasteur, 25 Rue du Dr Roux, 75015 Paris, France

For all author emails, please log on.

BMC Genomics 2010, 11:696  doi:10.1186/1471-2164-11-696

Published: 8 December 2010

Abstract

Background

Pax3 is a key upstream regulator of the onset of myogenesis, controlling progenitor cell survival and behaviour as well as entry into the myogenic programme. It functions in the dermomyotome of the somite from which skeletal muscle derives and in progenitor cell populations that migrate from the somite such as those of the limbs. Few Pax3 target genes have been identified. Identifying genes that lie genetically downstream of Pax3 is therefore an important endeavour in elucidating the myogenic gene regulatory network.

Results

We have undertaken a screen in the mouse embryo which employs a Pax3GFP allele that permits isolation of Pax3 expressing cells by flow cytometry and a Pax3PAX3-FKHR allele that encodes PAX3-FKHR in which the DNA binding domain of Pax3 is fused to the strong transcriptional activation domain of FKHR. This constitutes a gain of function allele that rescues the Pax3 mutant phenotype. Microarray comparisons were carried out between Pax3GFP/+ and Pax3GFP/PAX3-FKHR preparations from the hypaxial dermomyotome of somites at E9.5 and forelimb buds at E10.5. A further transcriptome comparison between Pax3-GFP positive and negative cells identified sequences specific to myogenic progenitors in the forelimb buds. Potential Pax3 targets, based on changes in transcript levels on the gain of function genetic background, were validated by analysis on loss or partial loss of function Pax3 mutant backgrounds. Sequences that are up- or down-regulated in the presence of PAX3-FKHR are classified as somite only, somite and limb or limb only. The latter should not contain sequences from Pax3 positive neural crest cells which do not invade the limbs. Verification by whole mount in situ hybridisation distinguishes myogenic markers. Presentation of potential Pax3 target genes focuses on signalling pathways and on transcriptional regulation.

Conclusions

Pax3 orchestrates many of the signalling pathways implicated in the activation or repression of myogenesis by regulating effectors and also, notably, inhibitors of these pathways. Important transcriptional regulators of myogenesis are candidate Pax3 targets. Myogenic determination genes, such as Myf5 are controlled positively, whereas the effect of Pax3 on genes encoding inhibitors of myogenesis provides a potential brake on differentiation. In the progenitor cell population, Pax7 and also Hdac5 which is a potential repressor of Foxc2, are subject to positive control by Pax3.